Literature DB >> 24730055

Chronic desipramine treatment rescues depression-related, social and cognitive deficits in Engrailed-2 knockout mice.

J Brielmaier, J M Senerth, J L Silverman, P G Matteson, J H Millonig, E DiCicco-Bloom, J N Crawley.   

Abstract

Engrailed-2 (En2) is a homeobox transcription factor that regulates neurodevelopmental processes including neuronal connectivity and elaboration of monoaminergic neurons in the ventral hindbrain. We previously reported abnormalities in brain noradrenergic concentrations in En2 null mutant mice that were accompanied by increased immobility in the forced swim test, relevant to depression. An EN2 genetic polymorphism has been associated with autism spectrum disorders, and mice with a deletion in En2 display social abnormalities and cognitive deficits that may be relevant to multiple neuropsychiatric conditions. This study evaluated the ability of chronic treatment with desipramine (DMI), a selective norepinephrine (NE) reuptake inhibitor and classical antidepressant, to reverse behavioral abnormalities in En2−/− mice. Desipramine treatment significantly reduced immobility in the tail suspension and forced swim tests, restored sociability in the three-chambered social approach task and reversed impairments in contextual fear conditioning in En2−/− mice. Our findings indicate that modulation of brain noradrenergic systems rescues the depression-related phenotype in En2−/− mice and suggest new roles for NE in the pathophysiology of the social and cognitive deficits seen in neuropsychiatric disorders such as autism or schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24730055      PMCID: PMC4004968          DOI: 10.1111/gbb.12115

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  41 in total

Review 1.  The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects.

Authors:  Bernardo Dell'Osso; M Carlotta Palazzo; Lucio Oldani; A Carlo Altamura
Journal:  CNS Neurosci Ther       Date:  2010-12-14       Impact factor: 5.243

2.  Cut-like homeobox 1 and nuclear factor I/B mediate ENGRAILED2 autism spectrum disorder-associated haplotype function.

Authors:  Jiyeon Choi; Myka R Ababon; Paul G Matteson; James H Millonig
Journal:  Hum Mol Genet       Date:  2011-12-16       Impact factor: 6.150

3.  The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism.

Authors:  C Lord; S Risi; L Lambrecht; E H Cook; B L Leventhal; P C DiLavore; A Pickles; M Rutter
Journal:  J Autism Dev Disord       Date:  2000-06

4.  High frequencies of de novo CNVs in bipolar disorder and schizophrenia.

Authors:  Dheeraj Malhotra; Shane McCarthy; Jacob J Michaelson; Vladimir Vacic; Katherine E Burdick; Seungtai Yoon; Sven Cichon; Aiden Corvin; Sydney Gary; Elliot S Gershon; Michael Gill; Maria Karayiorgou; John R Kelsoe; Olga Krastoshevsky; Verena Krause; Ellen Leibenluft; Deborah L Levy; Vladimir Makarov; Abhishek Bhandari; Anil K Malhotra; Francis J McMahon; Markus M Nöthen; James B Potash; Marcella Rietschel; Thomas G Schulze; Jonathan Sebat
Journal:  Neuron       Date:  2011-12-22       Impact factor: 17.173

5.  Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008.

Authors: 
Journal:  MMWR Surveill Summ       Date:  2012-03-30

6.  Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor.

Authors:  E H Wong; M S Sonders; S G Amara; P M Tinholt; M F Piercey; W P Hoffmann; D K Hyslop; S Franklin; R D Porsolt; A Bonsignori; N Carfagna; R A McArthur
Journal:  Biol Psychiatry       Date:  2000-05-01       Impact factor: 13.382

7.  Engrailed homeobox genes regulate establishment of the cerebellar afferent circuit map.

Authors:  Roy V Sillitoe; Michael W Vogel; Alexandra L Joyner
Journal:  J Neurosci       Date:  2010-07-28       Impact factor: 6.167

8.  Autism-relevant social abnormalities and cognitive deficits in engrailed-2 knockout mice.

Authors:  Jennifer Brielmaier; Paul G Matteson; Jill L Silverman; Julia M Senerth; Samantha Kelly; Matthieu Genestine; James H Millonig; Emanuel DiCicco-Bloom; Jacqueline N Crawley
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

9.  Mutations causing syndromic autism define an axis of synaptic pathophysiology.

Authors:  Benjamin D Auerbach; Emily K Osterweil; Mark F Bear
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

10.  Enhanced sensitivity of the MRL/MpJ mouse to the neuroplastic and behavioral effects of chronic antidepressant treatments.

Authors:  Darrick T Balu; Georgia E Hodes; Brian T Anderson; Irwin Lucki
Journal:  Neuropsychopharmacology       Date:  2009-01-28       Impact factor: 7.853

View more
  14 in total

1.  GABAB Receptor Agonist R-Baclofen Reverses Social Deficits and Reduces Repetitive Behavior in Two Mouse Models of Autism.

Authors:  J L Silverman; M C Pride; J E Hayes; K R Puhger; H M Butler-Struben; S Baker; J N Crawley
Journal:  Neuropsychopharmacology       Date:  2015-03-10       Impact factor: 7.853

2.  Serotonin neuron abnormalities in the BTBR mouse model of autism.

Authors:  Yue-Ping Guo; Kathryn G Commons
Journal:  Autism Res       Date:  2016-08-01       Impact factor: 5.216

Review 3.  The Rodent Forced Swim Test Measures Stress-Coping Strategy, Not Depression-like Behavior.

Authors:  Kathryn G Commons; Aram B Cholanians; Jessica A Babb; Daniel G Ehlinger
Journal:  ACS Chem Neurosci       Date:  2017-03-22       Impact factor: 4.418

Review 4.  Psychoactive drug exposure during breastfeeding: a critical need for preclinical behavioral testing.

Authors:  Irving Zucker
Journal:  Psychopharmacology (Berl)       Date:  2018-03-16       Impact factor: 4.530

5.  Engrailed-2 (En2) deletion produces multiple neurodevelopmental defects in monoamine systems, forebrain structures and neurogenesis and behavior.

Authors:  Matthieu Genestine; Lulu Lin; Madel Durens; Yan Yan; Yiqin Jiang; Smrithi Prem; Kunal Bailoor; Brian Kelly; Patricia K Sonsalla; Paul G Matteson; Jill Silverman; Jacqueline N Crawley; James H Millonig; Emanuel DiCicco-Bloom
Journal:  Hum Mol Genet       Date:  2015-07-28       Impact factor: 6.150

6.  Evaluation of the neuroactive steroid ganaxolone on social and repetitive behaviors in the BTBR mouse model of autism.

Authors:  Tatiana M Kazdoba; Randi J Hagerman; Dorota Zolkowska; Michael A Rogawski; Jacqueline N Crawley
Journal:  Psychopharmacology (Berl)       Date:  2015-11-03       Impact factor: 4.530

7.  Long-term exposure to intranasal oxytocin in a mouse autism model.

Authors:  K L Bales; M Solomon; S Jacob; J N Crawley; J L Silverman; R H Larke; E Sahagun; K R Puhger; M C Pride; S P Mendoza
Journal:  Transl Psychiatry       Date:  2014-11-11       Impact factor: 6.222

Review 8.  The role of cerebellar circuitry alterations in the pathophysiology of autism spectrum disorders.

Authors:  Matthew W Mosconi; Zheng Wang; Lauren M Schmitt; Peter Tsai; John A Sweeney
Journal:  Front Neurosci       Date:  2015-09-01       Impact factor: 4.677

9.  GH Dysfunction in Engrailed-2 Knockout Mice, a Model for Autism Spectrum Disorders.

Authors:  Giovanni Provenzano; Elena Clementi; Sacha Genovesi; Manuela Scali; Prem Prakash Tripathi; Paola Sgadò; Yuri Bozzi
Journal:  Front Pediatr       Date:  2014-09-01       Impact factor: 3.418

10.  Comparative Gene Expression Analysis of Two Mouse Models of Autism: Transcriptome Profiling of the BTBR and En2 (-/-) Hippocampus.

Authors:  Giovanni Provenzano; Zelia Corradi; Katia Monsorno; Tarcisio Fedrizzi; Laura Ricceri; Maria L Scattoni; Yuri Bozzi
Journal:  Front Neurosci       Date:  2016-08-25       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.